Dow Jones
35.430,42 +13,44 (+0,04%) Nasdaq
14.258,49 -23,27 (-0,16%) Nikkei 225
33.337,32 +16,10 (+0,05%) EUR/USD
1,0973 -0,0001 (-0,01%) Bitcoin EUR
34.692,76 +139,71 (+0,40%) CMC Crypto 200
785,44 -0,06 (-0,01%)
Illumina, Inc. (0J8Z.L)
| Chiusura precedente | 96,29 |
| Aperto | 0,00 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 0,00 - 0,00 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | 3.265 |
| Capitalizzazione | 152,078M |
| Beta (5 anni mensile) | 1,16 |
| Rapporto PE (ttm) | 0,22 |
| EPS (ttm) | 4,55 |
| Prossima data utili | 05 feb 2024 - 09 feb 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireMyriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
Myriad can conduct prospective clinical trials using Illumina’s TruSight Oncology Comprehensive Investigational Use Only testSALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two key milestones in its strategic partnership with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, to advance and support clinical research for gene-based, targeted thera
- GlobeNewswire
Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
Strategic partnership offers a unique combination of diagnostic development and commercialization capabilities to the pharmaceutical industrySALT LAKE CITY, March 02, 2023 (GLOBE NEWSWIRE) -- Myriad Genetic, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the expansion of a strategic partnership to broaden access to and availability of oncology homologous rec
